A study of Ofatumumab versus Rituximab in Hodgkin Lymphoma

Update Il y a 4 ans
Reference: U1111-1148-8535

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

To compare progression-free survival following therapy with single agent ofatumumab versus single agent rituximab in subjects with iNHL that has relapsed after prior rituximab-containing therapy.


Inclusion criteria

  • Indolent B-cell Non-Hodgkin’s Lymphoma